Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro
Copyright © 2023 Elsevier Inc. All rights reserved..
Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of 75 or cannot tolerate standard chemotherapy. Despite high response rates to these therapies, most patients succumb to the disease due to relapse and/or drug resistance, providing an unmet clinical need for novel therapies to improve AML patient survival. ME-344 is a potent isoflavone with demonstrated inhibitory activity toward oxidative phosphorylation (OXPHOS) and clinical activity in solid tumors. Given that OXPHOS inhibition enhances VEN antileukemic activity against AML, we hypothesized that ME-344 could enhance the anti-AML activity of VEN. Here we report that ME-344 enhanced VEN to target AML cell lines and primary patient samples while sparing normal hematopoietic cells. Cooperative suppression of OXPHOS was detected in a subset of AML cell lines and primary patient samples. Metabolomics analysis revealed a significant reduction of purine biosynthesis metabolites by ME-344. Further, lometrexol, a purine biosynthesis inhibitor, synergistically enhanced VEN-induced apoptosis in AML cell lines. Interestingly, AML cells with acquired AraC resistance showed significantly increased purine biosynthesis metabolites and sensitivities to ME-344. Furthermore, synergy between ME-344 and VEN was preserved in these AraC-resistant AML cells. In vivo studies revealed significantly prolonged survival upon combination therapy of ME-344 and VEN in NSGS mice bearing parental or AraC-resistant MV4-11 leukemia compared to the vehicle control. This study demonstrates that ME-344 enhances VEN antileukemic activity against preclinical models of AML by suppressing OXPHOS and/or purine biosynthesis.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:220 |
|---|---|
| Enthalten in: |
Biochemical pharmacology - 220(2024) vom: 27. Jan., Seite 115981 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hurrish, Katie H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
843G0TDV51 |
|---|
| Anmerkungen: |
Date Completed 29.01.2024 Date Revised 29.01.2024 published: Print-Electronic UpdateOf: Res Sq. 2023 Apr 28;:. - PMID 37162954 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bcp.2023.115981 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365721379 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365721379 | ||
| 003 | DE-627 | ||
| 005 | 20240129232016.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bcp.2023.115981 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1274.xml |
| 035 | |a (DE-627)NLM365721379 | ||
| 035 | |a (NLM)38081370 | ||
| 035 | |a (PII)S0006-2952(23)00574-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hurrish, Katie H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2024 | ||
| 500 | |a Date Revised 29.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: Res Sq. 2023 Apr 28;:. - PMID 37162954 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of 75 or cannot tolerate standard chemotherapy. Despite high response rates to these therapies, most patients succumb to the disease due to relapse and/or drug resistance, providing an unmet clinical need for novel therapies to improve AML patient survival. ME-344 is a potent isoflavone with demonstrated inhibitory activity toward oxidative phosphorylation (OXPHOS) and clinical activity in solid tumors. Given that OXPHOS inhibition enhances VEN antileukemic activity against AML, we hypothesized that ME-344 could enhance the anti-AML activity of VEN. Here we report that ME-344 enhanced VEN to target AML cell lines and primary patient samples while sparing normal hematopoietic cells. Cooperative suppression of OXPHOS was detected in a subset of AML cell lines and primary patient samples. Metabolomics analysis revealed a significant reduction of purine biosynthesis metabolites by ME-344. Further, lometrexol, a purine biosynthesis inhibitor, synergistically enhanced VEN-induced apoptosis in AML cell lines. Interestingly, AML cells with acquired AraC resistance showed significantly increased purine biosynthesis metabolites and sensitivities to ME-344. Furthermore, synergy between ME-344 and VEN was preserved in these AraC-resistant AML cells. In vivo studies revealed significantly prolonged survival upon combination therapy of ME-344 and VEN in NSGS mice bearing parental or AraC-resistant MV4-11 leukemia compared to the vehicle control. This study demonstrates that ME-344 enhances VEN antileukemic activity against preclinical models of AML by suppressing OXPHOS and/or purine biosynthesis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute myeloid leukemia | |
| 650 | 4 | |a ME-344 | |
| 650 | 4 | |a Oxidative phosphorylation | |
| 650 | 4 | |a Purine biosynthesis | |
| 650 | 4 | |a Venetoclax | |
| 650 | 7 | |a venetoclax |2 NLM | |
| 650 | 7 | |a N54AIC43PW |2 NLM | |
| 650 | 7 | |a ME-344 |2 NLM | |
| 650 | 7 | |a 843G0TDV51 |2 NLM | |
| 650 | 7 | |a Bridged Bicyclo Compounds, Heterocyclic |2 NLM | |
| 650 | 7 | |a Isoflavones |2 NLM | |
| 650 | 7 | |a Purines |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 700 | 1 | |a Su, Yongwei |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Shraddha |e verfasserin |4 aut | |
| 700 | 1 | |a Ramage, Cassandra L |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jianlei |e verfasserin |4 aut | |
| 700 | 1 | |a Temby, Brianna R |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Jenna L |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Holly |e verfasserin |4 aut | |
| 700 | 1 | |a Buck, Steven A |e verfasserin |4 aut | |
| 700 | 1 | |a Wiley, Sandra E |e verfasserin |4 aut | |
| 700 | 1 | |a Hüttemann, Maik |e verfasserin |4 aut | |
| 700 | 1 | |a Polin, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Kushner, Juiwanna |e verfasserin |4 aut | |
| 700 | 1 | |a Dzinic, Sijana H |e verfasserin |4 aut | |
| 700 | 1 | |a White, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Xun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Boerner, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Zhanjun |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Atrash, Gheath |e verfasserin |4 aut | |
| 700 | 1 | |a Konoplev, Sergej N |e verfasserin |4 aut | |
| 700 | 1 | |a Busquets, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Tiziani, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Matherly, Larry H |e verfasserin |4 aut | |
| 700 | 1 | |a Taub, Jeffrey W |e verfasserin |4 aut | |
| 700 | 1 | |a Konopleva, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Yubin |e verfasserin |4 aut | |
| 700 | 1 | |a Baran, Natalia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochemical pharmacology |d 1959 |g 220(2024) vom: 27. Jan., Seite 115981 |w (DE-627)NLM000000094 |x 1873-2968 |7 nnns |
| 773 | 1 | 8 | |g volume:220 |g year:2024 |g day:27 |g month:01 |g pages:115981 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bcp.2023.115981 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 220 |j 2024 |b 27 |c 01 |h 115981 | ||